Over the past 25 years, BIOQUAL has held, and currently holds, several long term government contracts which utilize the nonhuman primate model to study assorted human diseases. Studies have involved:
- Hepatitis A through Hepatitis E including studies to isolate and treat the virus, characterize potentially new viruses and evaluate candidate Hepatitis vaccines.
- Studies of various re-assortment influenza viruses, human respiratory syncytial viruses and Rotaviruses with a primary objective of developing and evaluating candidate vaccines to treat these conditions.
- Studies involving Immunodeficiency Virus, HIV and SIV, to define the AIDS pathogenicity and development of therapeutics and candidate vaccines.
- Studies involving Simian Immunodeficiency Virus (SIV) and AIDS to define the pathogenicity and development of therapeutics and candidate vaccines.
- Studies of the nonhuman primate response to HIV-1, HIV-2 and SIV using mutants of the virus with the objective of providing insight into protection afforded by candidate vaccines.
- Studies of Endocrine effects of related contraceptive drugs.
- Studies associated with topical Microbicide development and efficacy testing.
- Studies to determine affects of environmental enrichment and social housing.
Contact
Mark G. Lewis, Ph.D.
President
Director of Research
BIOQUAL, Inc.
9600 Medical Center Drive
Rockville, MD 20850-3336
Phone: (301) 251-2801
Fax: (301) 251-1260
Small Laboratory Animal Sciences
Reproductive Endocrinology and Toxicology
Infectious Disease Research
In Vitro Laboratory Services
Environmental Enrichment and Behavior
GLP Studies
Partnerships for Contracts and Grants